<DOC>
	<DOCNO>NCT02644421</DOCNO>
	<brief_summary>Double-blind , crossover , randomize , 3x3 Latin square , placebo-controlled study single intravenous dose administration VVZ-149 . To demonstrate assay sensitivity , lidocaine administer positive control . The study take place single inpatient visit involve three separate treatment period , washout ( &gt; 16-hours . Study drug ( VVZ-149 vs. lidocaine vs. normal saline , NS ) administer intravenously .</brief_summary>
	<brief_title>Clinical Trial Evaluate Safety Analgesic Efficacy VVZ-149 Lumbar Radiculopathy ( Sciatica )</brief_title>
	<detailed_description />
	<mesh_term>Radiculopathy</mesh_term>
	<mesh_term>Sciatica</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>1 . Subjects must history persistent pain secondary unilateral monoradiculopathy present minimum 3 month prior study , average pain intensity score least moderate least 50 % day 7 day prior screen visit 7 day prior start study medication . 2 . Males females 18 70 year age , inclusive . Females pregnant breastfeeding exclude trial . 3 . Subjects must generally good health , either use medication use stabilized medication regimen chronic wellcontrolled condition hypertension , allergy , stable endocrinopathies ( e.g . hypothyroidism ) , etc . Subjects active disease review casebycase basis principal investigator . 4 . No concomitant therapy medication know significant inhibitor inducer CYP450 2D6 CYP3A4 , discretion PI . 5 . Normal clinically insignificant screen laboratory test : Serum BUN , creatinine , bicarbonate , calcium , chloride , potassium , sodium , lactate dehydrogenase , inorganic phosphate , total protein , glucose , albumin , uric acid . WBC , absolute neutrophil count , hemoglobin , hematocrit , platelet . SGOT ( AST ) , SGPT ( ALT ) , total bilirubin , alkaline phosphatase , TSH/T4 , urinalysis , urine toxicology screen . Electrocardiogram ( 12lead ) . Any significant laboratory abnormality review principal investigator prior inclusion subject study . 6 . Willingness restrict analgesic therapy inpatient admission day allow rescue analgesic agent permit study ( acetaminophen ) . 7 . Subjects must normal cognitive function communicative ability English language . 8 . Subjects must able provide meaningful write informed consent . 9 . Subjects must able maintain complete require questionnaire , must able fulfill condition protocol . 1 . Female subject pregnant breastfeeding , plan become pregnant participate study . 2 . Subjects previous history multiple severe drug allergy , include lidocaine . 3 . Subjects history current chronic substance abuse , include alcohol . 4 . Subjects participate study investigational drug device within 30 day prior screen study . Subjects must agree participate investigational drug device study entire course study ( begin screen visit ) . 5 . Subjects follow abnormal clinical evaluation : Impaired renal function define BUN &gt; 45 creatinine &gt; 2.0 and/or impair liver function define liver transaminase , alkaline phosphatase , bilirubin great 1.5 x upper limit normal laboratory value . Prolonged PR ( &gt; 200 m ) interval electrocardiogram ( 12lead ) . Subjects present laboratory abnormality may allow casebycase basis discretion principal investigator . 6 . Subjects intend donate blood blood product participate study , 30 day follow completion study . 7 . Subjects clinically significant renal , hepatic , cardiac disease , seizure disorder , clinical history lifethreatening arrhythmia ( i.e . torsades de pointes ) . 8 . Subjects severe neuropsychiatric disorder require treatment . 9 . Subjects sensitivity amidetype local anesthetic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Sciatica</keyword>
</DOC>